Kemp Dolliver

Stock Analyst at Brookline Capital

(0.49)
# 4,138
Out of 5,044 analysts
16
Total ratings
33.33%
Success rate
-18.04%
Average return

Stocks Rated by Kemp Dolliver

Rein Therapeutics
Aug 19, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.55
Upside: -
Radiopharm Theranostics
Jul 21, 2025
Initiates: Buy
Price Target: $18
Current: $5.01
Upside: +259.28%
Lisata Therapeutics
Jul 15, 2025
Maintains: Buy
Price Target: $20$32
Current: $2.66
Upside: +1,103.01%
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $3.61
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $1.54
Upside: +133.77%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.02
Upside: +1,682.18%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.28
Upside: +2,353.13%
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $55.88
Upside: +78.95%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.07
Upside: +2,653.62%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $7.70
Upside: +224.68%
Initiates: Buy
Price Target: $19
Current: $5.04
Upside: +272.02%
Assumes: Buy
Price Target: $8
Current: $0.69
Upside: +1,064.65%
Initiates: Buy
Price Target: $5.65
Current: $0.75
Upside: +656.56%